InStockRx raises $5 million to scale pharmacy-to-pharmacy marketplace

InStockRx closed a $5 million Series A in June 2026 to expand its verified pharmacy marketplace for trading brand medications. The funding comes as pharmacies face tighter margins, inventory imbalances and supply pressure, and the platform says it is already serving more than 1,600 pharmacies.

Why it matters: - Pharmacies are under pressure from rising costs, supply constraints and excess inventory. - InStockRx aims to help pharmacies recover cash from surplus brand medications and source needed stock from verified peers. - The platform says buyers can save up to 40% on brand medications and typically pay 30% less than NADAC reference pricing.

What happened: - InStockRx announced a $5 million Series A led by FCA Venture Partners. - Techstars Boston and additional investors also participated. - The round closed in June 2026. - The company is based in New Egypt, New Jersey. - InStockRx is a pharmacy-to-pharmacy marketplace where verified pharmacies buy and sell brand medications directly with one another.

The details: - InStockRx says every trade generates T3 documentation to support DSCSA requirements. - The T3 packet includes Transaction Information, Transaction History and Transaction Statement. - The platform serves more than 1,600 verified pharmacies, including independent drugstores and multi-location operators. - Transaction volume has been growing 50% month over month. - Listings sell in about five days on average. - Pharmacies can join for free and pay only when they sell. - Trading Partner Groups let pharmacies build private networks with preferred partners. - Pharmacy Concierge support helps with buying and selling. - The platform works with any pharmacy management system. - Inventory listed on InStockRx comes only from verified pharmacies. - The company says sellers can turn surplus brand medications into recovered cash while buyers can source stock from trusted pharmacies. - The company says buyers can save up to 40% on brand medications. - InStockRx says the average buying pharmacy saves 30% versus NADAC reference pricing on brand medications. - Savings are calculated as the difference between the verified-pharmacy transaction price on the InStockRx network and the corresponding NADAC reference price published by CMS at the time of transaction. - NADAC reference pricing is a public benchmark and does not reflect a pharmacy's negotiated wholesaler price. - InStockRx says the funding will support expansion as pharmacies face tighter supply and margin pressure.

Between the lines: - The raise gives InStockRx fresh capital to expand a niche marketplace built around trust, compliance and inventory efficiency. - The company is positioning pharmacy-to-pharmacy trading as a way to reduce waste and keep more medication available for patients. - FCA Venture Partners is backing a model that cuts system costs while preserving pharmacy margins. - Techstars Boston's participation adds validation because InStockRx is a Techstars Boston graduate.

What's next: - InStockRx plans to use the capital to expand to more pharmacies and larger operators and organizations. - The company also plans to keep building the network for pharmacies of every size. - InStockRx directs readers to more information.